About: SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism
Creator	Guo, Deyin Tao, Jiali Lu, Xiaolu Pan, Ji’an
Source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus (SARS-CoV) encodes a highly basic nucleocapsid (N) protein which can inhibit the synthesis of type I interferon (IFN), but the molecular mechanism of this antagonism remains to be identified. In this study, we demonstrated that the N protein of SARS-CoV could inhibit IFN-beta (IFN-β) induced by poly(I:C) or Sendai virus. However, we found that N protein could not inhibit IFN-β production induced by overexpression of downstream signaling molecules of two important IFN-β induction pathways, toll-like receptor 3 (TLR3)- and RIG-I-like receptors (RLR)-dependent pathways. These results indicate that SARS-CoV N protein targets the initial step, probably the cellular PRRs (pattern recognition receptors)-RNAs-recognition step in the innate immune pathways, to suppress IFN expression responses. In addition, co-immunoprecipitation assays revealed that N protein did not interact with RIG-I or MDA5. Further, an assay using truncated mutants revealed that the C-terminal domain of N protein was critical for its antagonism of IFN induction, and the N deletion mutant impaired for RNA-binding almost completely lost the IFN-β antagonist activity. These results contribute to our further understanding of the pathogenesis of SARS-CoV.
has issue date	2010-10-26(xsd:dateTime)
bibo:doi	10.1007/s11262-010-0544-x
bibo:pmid	20976535
has license	no-cc
schema:url	https://doi.org/10.1007/s11262-010-0544-x
resource representing a document's title	SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism
has PubMed Central identifier	PMC7088804
has PubMed identifier	20976535
schema:publication	Virus Genes
resource representing a document's body	covid:PMC7088804#body_text
is schema:about of	named entity 'RESPONSE' named entity 'induction' named entity 'INITIAL' named entity 'REGION' named entity 'SARS-COV' named entity 'INDUCTION' named entity 'TARGETING' named entity 'CRITICAL' named entity 'STEP' named entity 'PATHWAY' named entity 'ANTAGONISM' named entity 'NUCLEOCAPSID PROTEIN' named entity 'IFN' named entity 'ITS' named entity 'C-TERMINAL' named entity 'PROTEIN ' named entity 'C-terminal' named entity 'IFN' named entity 'vector' named entity 'RNAs' named entity 'protein' named entity 'IRF-3' named entity 'IKKε' named entity 'SARS-CoV' named entity 'single-stranded RNA' named entity 'HCV' named entity 'IFN-β' named entity 'RIG-I' named entity 'protein' named entity 'luciferase' named entity 'IFN-β' named entity 'RLR' named entity 'C-terminal' named entity 'RNA-binding' named entity 'endosomal' named entity 'host defense mechanisms' named entity 'innate immune response' named entity 'gene' named entity 'transfected' named entity 'reagent' named entity 'pathogenicity' named entity 'RIG-I' named entity 'IFN-β' named entity '293T cells' named entity 'Promega' named entity 'IFN' named entity 'Assay' named entity 'real-time PCR' named entity 'Myc' named entity 'PRRs' named entity 'IFN-β' named entity 'TRIF' named entity 'mRNA synthesis' named entity 'RIG-I' named entity 'protein' named entity 'MDA5' named entity 'transfected' named entity 'downregulate' named entity 'Myc-tag' named entity 'IFN' named entity 'protein' named entity 'plasmid' named entity 'cellular pathways' named entity 'MDA5' named entity 'TRIF' named entity 'TLR3' named entity 'IFN-β' named entity 'C-terminal domain' named entity 'translocation' named entity 'cDNA' named entity 'mortality rate' named entity 'IFN-β' named entity 'IFN-β' named entity 'luciferase' named entity 'MyD88' named entity 'constitutively active' named entity 'mRNA' named entity 'DAPI' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software